Cancer Med March 2023 PMID 36420712

Estimating recurrences prevented and costs avoided with atezolizumab in early non-small cell lung cancer in the United States.

Rishika Sharma, Sarika Ogale, Nathaniel J Smith, Janet Shin Lee

Full text PDF Download social card

Mentions

Peak: 1 in Nov 2022

across 3 sources since Nov 2022

Extended reach

1,940

potential audience

Total likes

Video views

Mentions per month

Nov 2022 – Jul 2023

Where it's discussed

Reddit2 posts
X / Twitter1 posts
YouTube1 videos

AI synopsis

What people are saying

Multiple discussions highlight the potential of atezolizumab to reduce recurrences and costs, with phrases like 'cost savings' and 'preventing relapses,' demonstrating understanding of the article’s findings. Participants’ tone suggests optimism and recognition of its importance in lung cancer treatment.

AgreementModerate agreement

Most discussions acknowledge the study’s positive findings on the benefits of atezolizumab, indicating general support.

InterestHigh interest

Posts show high interest, with participants expressing curiosity about the implications for treatment and healthcare costs.

EngagementModerate engagement

Many posts delve into the methods and broader implications, reflecting meaningful engagement.

ImpactHigh impact

The discussions suggest a strong perception of the study's significant impact on clinical practice and healthcare economics.

Abstract in brief

The study assesses how the cancer drug atezolizumab (ATZ), used after surgery for a specific type of lung cancer (early nonsmall cell lung cancer), can prevent recurrences and deaths, and save costs in the U.S.
Using a simulation model, researchers estimate that each year, about 4,400 eligible patients could be treated with ATZ, potentially preventing around 1,030 recurrences and 369 deaths over five years, along with significant healthcare savings.
Overall, the findings suggest that adjuvant ATZ not only improves patient outcomes by reducing cancer recurrence and mortality but also lowers the economic burden associated with treating recurring lung cancer.

Read the full abstract

All mentions

Cost-Effectiveness of Atezizumab in Early Non-Small Cell Lung Cancer Treatment

The study assesses how the cancer drug atezolizumab used after surgery for early non-small cell lung cancer can prevent recurrences and deaths, and save costs in the U.S. Researchers estimate that approximately 4,400…

Social RTCL TV · Jul 23, 2023 14 views

ThoraicH

@ThoraicH · X

Estimating recurrences prevented and costs avoided with atezolizumab in early non-small cell lung cancer in the Uni… https://t.co/HPe0SnMFM2 https://t.co/Z4ZqOsmPNn

Nov 25, 2022 · 1,927 followers View post →